INT83886

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 27
Total Number 27
Disease Relevance 11.69
Pain Relevance 10.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (HMOX2) oxidoreductase activity (HMOX2) endoplasmic reticulum (HMOX2)
plasma membrane (HMOX2) transmembrane transport (HMOX2)
Anatomy Link Frequency
macrophages 1
articular 1
monocytes 1
muscle 1
platelet 1
HMOX2 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 212 99.76 Very High Very High Very High
tramadol 5 99.76 Very High Very High Very High
Pain 88 99.32 Very High Very High Very High
aspirin 55 99.20 Very High Very High Very High
Analgesic 15 99.12 Very High Very High Very High
Arthritis 44 99.08 Very High Very High Very High
rheumatoid arthritis 92 99.00 Very High Very High Very High
COX2 7 98.96 Very High Very High Very High
COX-2 inhibitor 44 98.92 Very High Very High Very High
Paracetamol 4 98.78 Very High Very High Very High
Disease Link Frequency Relevance Heat
Prostate Cancer 3 99.84 Very High Very High Very High
Apoptosis 11 99.56 Very High Very High Very High
INFLAMMATION 107 99.48 Very High Very High Very High
Pain 108 99.32 Very High Very High Very High
Arthritis 48 99.08 Very High Very High Very High
Rheumatoid Arthritis 95 99.00 Very High Very High Very High
Rheumatic Diseases 2 98.36 Very High Very High Very High
Osteoarthritis 124 98.12 Very High Very High Very High
Arthropathy 4 97.68 Very High Very High Very High
Gastroesophageal Reflux Disease 13 97.60 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Rofecoxib selectively inhibits cyclo-oxygenase-2 in a dose-dependent manner in humans.
Negative_regulation (inhibits) of cyclo-oxygenase-2
1) Confidence 0.43 Published 1999 Journal Drugs Section Abstract Doc Link 10493277 Disease Relevance 0.15 Pain Relevance 0.11
We assessed the effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, and tramadol, a centrally acting analgesic, on both delayed-onset muscle soreness (DOMS) and experimentally induced ischaemic pain.
Negative_regulation (inhibitor) of cyclo-oxygenase-2 in muscle associated with pain, tramadol, analgesic and myalgia
2) Confidence 0.43 Published 2005 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 16462914 Disease Relevance 0.65 Pain Relevance 0.69
New therapeutic approaches include the use of cyclo-oxygenase-2 inhibitors, and intra-articular hyaluronans (HA).
Negative_regulation (inhibitors) of cyclo-oxygenase-2 in articular
3) Confidence 0.43 Published 2000 Journal Curr Rheumatol Rep Section Abstract Doc Link 11123099 Disease Relevance 0.59 Pain Relevance 0.39
Celecoxib is a new cyclo-oxygenase-2 inhibitor recently approved for arthritis.
Negative_regulation (inhibitor) of cyclo-oxygenase-2 associated with arthritis
4) Confidence 0.43 Published 2001 Journal J. Am. Acad. Dermatol. Section Abstract Doc Link 11464196 Disease Relevance 0.58 Pain Relevance 0.05
Etoricoxib is a new cyclo-oxygenase-2 inhibitor with a long duration of action and a lack of a deteriorating effect on platelet function.
Negative_regulation (inhibitor) of cyclo-oxygenase-2 in platelet
5) Confidence 0.36 Published 2007 Journal Acta Anaesthesiol Scand Section Abstract Doc Link 17155937 Disease Relevance 0.26 Pain Relevance 0.26
The NSAID etoricoxib is a selective inhibitor of cyclo-oxygenase 2 (COX-2), approved for treatment of patients with chronic arthropathies and musculoskeletal and dental pain.
Negative_regulation (inhibitor) of cyclo-oxygenase 2 associated with pain, cinod and arthropathy
6) Confidence 0.22 Published 2008 Journal Clin Pharmacokinet Section Abstract Doc Link 18840026 Disease Relevance 0.19 Pain Relevance 0.20
Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), is the first specific inhibitor of cyclo-oxygenase-2 (COX-2) approved to treat patients with rheumatism and osteoarthritis.
Negative_regulation (inhibitor) of cyclo-oxygenase-2 associated with inflammation, rheumatism, cinod and osteoarthritis
7) Confidence 0.16 Published 2000 Journal Clin Pharmacokinet Section Abstract Doc Link 10749518 Disease Relevance 0.30 Pain Relevance 0.57
BACKGROUND: Much recent effort has been made to produce selective inhibitors of cyclo-oxygenase-2 (COX-2) in the belief that these will lack the gastrointestinal damaging effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs).
Negative_regulation (inhibitors) of cyclo-oxygenase-2 associated with inflammation and cinod
8) Confidence 0.13 Published 1999 Journal Aliment. Pharmacol. Ther. Section Abstract Doc Link 10468690 Disease Relevance 0.26 Pain Relevance 0.42
Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.
Negative_regulation (inhibitor) of cyclo-oxygenase-2 associated with cox2
9) Confidence 0.12 Published 2000 Journal Clin Pharmacokinet Section Title Doc Link 10749518 Disease Relevance 0.29 Pain Relevance 0.64
These derivatives selectively inhibited cyclo-oxygenase-2 (COX-2) activity in human monocytes being Me-UCH 5 the most potent (IC50 0.06 microM).
Negative_regulation (inhibited) of cyclo-oxygenase-2 in monocytes
10) Confidence 0.09 Published 2006 Journal Life Sci. Section Abstract Doc Link 16360707 Disease Relevance 0 Pain Relevance 0.05
Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase.
Negative_regulation (inhibitors) of cyclo-oxygenase-2 associated with cox2
11) Confidence 0.09 Published 2006 Journal Life Sci. Section Title Doc Link 16360707 Disease Relevance 0 Pain Relevance 0.10
Recent data have suggested that regular consumption of nonsteroid anti-inflammatory drugs (NSAIDs), particularly selective inhibitors of cyclo-oxygenase-2 (COX-2), is associated with an increased risk of thrombotic events.
Negative_regulation (inhibitors) of cyclo-oxygenase-2 associated with inflammation and cinod
12) Confidence 0.08 Published 2006 Journal FASEB J. Section Abstract Doc Link 17142796 Disease Relevance 0.17 Pain Relevance 0.43
CONCLUSIONS: The preferential inhibition of cyclo-oxygenase 2 by nabumetone was postulated to afford better clinical efficacy and gastrointestinal tolerability in osteoarthritis as compared to aceclofenac.


Negative_regulation (inhibition) of cyclo-oxygenase 2
13) Confidence 0.07 Published 2009 Journal JNMA J Nepal Med Assoc Section Body Doc Link 20387351 Disease Relevance 0 Pain Relevance 0
The introduction of selective inhibitors of cyclo-oxygenase-2 (COX-2) has provided effective treatment of inflammatory arthritis and musculoskeletal pain, with dramatic reductions in the risk of GI adverse events.
Negative_regulation (inhibitors) of cyclo-oxygenase-2 associated with pain, inflammation and arthritis
14) Confidence 0.06 Published 2003 Journal Can. J. Gastroenterol. Section Abstract Doc Link 12772010 Disease Relevance 0.90 Pain Relevance 0.70
In experimental model systems and observational studies, aspirin and other NSAIDs have been reported to inhibit cyclo-oxygenase 2, increase apoptosis, decrease inflammation, decrease proliferation, and inhibit angiogenesis [4,26,27,105–111].
Negative_regulation (inhibit) of cyclo-oxygenase 2 associated with aspirin, inflammation, cinod and apoptosis
15) Confidence 0.05 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 1.32 Pain Relevance 0.43
Nabumetone, a recently developed preferential cyclo-oxygenase 2 inhibitor has also proved to be equally effective.
Negative_regulation (inhibitor) of cyclo-oxygenase 2
16) Confidence 0.05 Published 2009 Journal JNMA J Nepal Med Assoc Section Abstract Doc Link 20387351 Disease Relevance 0.36 Pain Relevance 0.32
CONCLUSIONS: Patients treated with a cyclo-oxygenase 2-specific inhibitor have a shorter recovery time when compared with patients on a standard postoperative PCA morphine-only regimen after colorectal resection.


Negative_regulation (inhibitor) of cyclo-oxygenase 2-specific
17) Confidence 0.05 Published 2007 Journal Colorectal Dis Section Body Doc Link 17181846 Disease Relevance 0 Pain Relevance 0
It is a Cyclo-oxygenase-2 inhibitor and is amply used as analgesic and anti-inflammatory drug having a half-life of 15â20 minutes [3].
Negative_regulation (inhibitor) of Cyclo-oxygenase-2 associated with inflammation and analgesic
18) Confidence 0.04 Published 2010 Journal Scientia Pharmaceutica Section Body Doc Link PMC3002828 Disease Relevance 0.47 Pain Relevance 0.55
Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor.
Negative_regulation (inhibitor) of cyclo-oxygenase-2
19) Confidence 0.04 Published 2003 Journal Clin Pharmacokinet Section Title Doc Link 12793839 Disease Relevance 0.07 Pain Relevance 0.19
The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review.
Negative_regulation (inhibitors) of cyclo-oxygenase-2 associated with prostate cancer
20) Confidence 0.03 Published 2005 Journal International journal of surgery (London, England) Section Title Doc Link 17462298 Disease Relevance 0.70 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox